comparemela.com

Latest Breaking News On - Arch biopartners inc - Page 5 : comparemela.com

Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

07.02.2023 - TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) - Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting .

Shares for Interest Debt Settlement

09.02.2022 - TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) - Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $424,767.07 in . Seite 1

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.